Gabapentin News and Research RSS Feed - Gabapentin News and Research

Gabapentin (brand name Neurontin) is a medication originally developed for the treatment of epilepsy. Presently, gabapentin is widely used to relieve pain, especially neuropathic pain.
XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

XenoPort, Inc. announced today that it has initiated a Phase 2 clinical trial of XP23829, its proprietary investigational next-generation fumaric acid product candidate. The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of XP23829 as a potential treatment of patients with moderate-to-severe chronic plaque-type psoriasis. [More]
Study determines effectiveness of gabapentin for treatment of vulvodynia in women

Study determines effectiveness of gabapentin for treatment of vulvodynia in women

A chronic syndrome called vulvodynia that affects from four to seven percent of women is being studied by physicians at The Women's Health Institute at Robert Wood Johnson Medical School, part of Rutgers, The State University of New Jersey, in hopes of alleviating sometimes excruciating pain. [More]
XenoPort reports net loss of $19.1 million for fourth quarter 2013

XenoPort reports net loss of $19.1 million for fourth quarter 2013

XenoPort, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2013. Revenues for the fourth quarter were $2.9 million, compared to $0.5 million for the same period in 2012. Net loss for the fourth quarter was $19.1 million compared to net income of $3.0 million that resulted from a non-cash gain from XenoPort's litigation settlement with Glaxo Group Limited in the fourth quarter of 2012. At December 31, 2013, XenoPort had cash and cash equivalents and short-term investments of $58.7 million. [More]
FDA-approved drug pregabalin effectively treats RLS symptoms with less side effects

FDA-approved drug pregabalin effectively treats RLS symptoms with less side effects

A report in the Feb. 13 New England Journal of Medicine confirms previous studies suggesting that long-term treatment with the type of drugs commonly prescribed to treat restless leg syndrome (RLS) can cause a serious worsening of the condition in some patients. [More]
Study sheds light on the biological underpinnings of obesity

Study sheds light on the biological underpinnings of obesity

A new neuroscience study sheds light on the biological underpinnings of obesity. The in vivo study, published in the January 8 issue of the Journal of Neuroscience, reveals how a protein in the brain helps regulate food intake and body weight. The findings reveal a potential new avenue for the treatment of obesity and may help explain why medications that are prescribed for epilepsy and other conditions that interfere with this protein, such as gabapentin and pregabalin, can cause weight gain. [More]
Doctors should consider underlying inflammatory conditions when selecting anti-epilepsy drugs, say researchers

Doctors should consider underlying inflammatory conditions when selecting anti-epilepsy drugs, say researchers

Physicians at the Ruhr-Universität Bochum (RUB) have been investigating if established anti-epilepsy drugs have anti-inflammatory or pro-inflammatory properties - an effect for which these pharmaceutical agents are not usually tested. [More]
Depomed reports financial results for third quarter 2013

Depomed reports financial results for third quarter 2013

Total revenues were $37.5 million and included recognition of a $5.0 million milestone payment from Mallinckrodt related to the NDA filing of MNK-795. Excluding this milestone and a $10 million upfront payment from Janssen in the third quarter of 2012, total revenues of $32.5 million grew 39% compared to $23.3 million for the third quarter of 2012. [More]
Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

The generic drug gabapentin, which is already widely prescribed for epilepsy and some kinds of pain, appears to be safe and effective in the treatment of alcohol dependence. The finding comes from a 150-patient randomized, placebo-controlled, double blind clinical trial conducted by scientists at The Scripps Research Institute. [More]
FDA accepts NDA for MNK-795 oral formulation

FDA accepts NDA for MNK-795 oral formulation

Depomed, Inc. (NASDAQ: DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-795. [More]
Depomed receives complete response letter for SEFELSA NDA

Depomed receives complete response letter for SEFELSA NDA

Depomed, Inc., a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration issued a complete response letter to the New Drug Application for SEFELSA, Depomed's investigational, oral, twice daily formulation of gabapentin to treat moderate to severe vasomotor symptoms due to menopause. [More]
XenoPort's Arbaclofen placarbil fails to meet co-primary endpoints in Phase 3 clinical trial

XenoPort's Arbaclofen placarbil fails to meet co-primary endpoints in Phase 3 clinical trial

XenoPort, Inc. announced today top-line results from its pivotal Phase 3 clinical trial of arbaclofen placarbil for the treatment of patients with spasticity due to multiple sclerosis. [More]
Nearly 1/10 stroke patients suffer from chronic and debilitating pain

Nearly 1/10 stroke patients suffer from chronic and debilitating pain

Nearly 1 in 10 stroke patients suffer chronic and debilitating pain, typically described as sharp, stabbing or burning. It's called central poststroke pain syndrome (CPSP). It was first described more than 100 years ago, and it is treatable with medications and magnetic or electrical stimulation of the brain. [More]
Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain is caused by lesion or disease to the peripheral somatosensory nervous system. Nerve damage that can lead to peripheral neuropathic pain can happen as a result of a range of different diseases, medications or traumatic injuries. [More]
Restless legs syndrome and insomnia: a possible explanation

Restless legs syndrome and insomnia: a possible explanation

Johns Hopkins researchers believe they may have discovered an explanation for the sleepless nights associated with restless legs syndrome (RLS), a symptom that persists even when the disruptive, overwhelming nocturnal urge to move the legs is treated successfully with medication. [More]
Anti-seizure drug benefits women with severe morning sickness

Anti-seizure drug benefits women with severe morning sickness

Good news may be on the horizon for Kate Middleton, Duchess of Cambridge, and other women stricken with severe nausea and vomiting during pregnancy, thanks to the work of a University at Buffalo professor who is conducting research on a drug that is showing success treating pregnant women with this condition. [More]
Spaniels' neuropathic pain condition stays static without surgery

Spaniels' neuropathic pain condition stays static without surgery

Cavalier King Charles with neuropathic pain induced by a condition characterized by a brain–skull size mismatch do not show significant improvement after nonsurgical treatment for the condition, indicate UK study results. [More]

Depomed third quarter 2012 revenue increases to $33.3 million

Depomed, Inc. today reported financial results for the quarter and nine months ended September 30, 2012. [More]

Favorable preliminary results from XenoPort’s XP23829 Phase 1 trial on RRMS, psoriasis

XenoPort, Inc. announced today favorable preliminary results from a Phase 1 clinical trial in healthy adults designed to assess the pharmacokinetics (PK), safety and tolerability of single doses of four different oral formulations of XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate (MMF). [More]
Limited positive effect of Tafamidis in neurological disorders

Limited positive effect of Tafamidis in neurological disorders

Tafamidis meglumine was approved in November 2011 for the treatment of transthyretin amyloidosis in adults. [More]
Unique approaches to improve pain management in hospitals and clinical practices

Unique approaches to improve pain management in hospitals and clinical practices

Five recent Johns Hopkins University School of Nursing DNP graduates have taken different and unique approaches in working to improve the implementation of pain management in hospitals and clinical practices. [More]